On November 2, 2022 Beijing Immunochina reported that it raised at least $28 million in a Series D+ round of to support the NDA filing and commercialization of its lead product, CAR-T IM19 (Press release, Immunochina, NOV 2, 2022, View Source [SID1234623091]). The IM19 molecule, a CD19 CAR-T immunotherapy, was tested in patients with B-Cell Acute Lymphoblastic Leukemia and Non Hodgkin’s Lymphoma. Simcere partners the drug. The company’s portfolio includes ten CAR-T assets. Immunochina’s latest financing was co-invested by Beijing Zhongguancun Science City Innovation Development and BCT Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!